Evidence map›Paper›PMID 31844838›Full record

ArticleAntibody therapeutics2019

Highlights of 2019 Protein Engineering Summit (PEGS) in Boston, USA: Advancing Antibody-Based Cancer Therapies to the Clinic.

Hong Li, You Li, Cheng Wang, Shouye Wang, Mitchell Ho

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antibody therapeutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Hong LiKlus Pharma, 8 Clarke Drive, Cranbury NJ 08512, USA.
You LiKey Laboratory of Medical Molecular Virology, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
Cheng WangCoWin Venture, Taikang Financial Tower 2917, Chaoyang District, Beijing, 100026, China.
Shouye WangChinese Antibody Society, 955 Massachusetts Ave #276, Cambridge, MA 02139, USA.
Mitchell HoNCI Antibody Engineering Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Japan Society · USNational Institutes of Health · USShanghai Medical College of Fudan University · CN

Funding

Development of new antibody-based cancer therapiesZIABC010891 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HO, MITCHELL · 2009 to 2025
$21.4M
Antibody Therapy of CancerZ01BC010891 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HO, MITCHELL · 2008 to 2008
$56k
Intramural NIH HHS Z01 BC010891Intramural NIH HHS Z99 CA999999Intramural NIH HHS ZIA BC010891
6 · The paper itself

Abstract

The 15

Indexed as

antibody platformbispecific antibodiesbispecific T-cell engagerbivalentcancer immunotherapycytotoxicityT-cell engagertumor associated antigen

Identifiers

PMID31844838
PMCPMC6913531
OpenAlexW2983494243

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.